$2.36
-0.02-0.84%
Last update: Nov 10, 7:49 PM
NRX Pharmaceuticals Inc
NRXPNASDAQ
NRX Pharmaceuticals fell 6.3% from $2.54 to $2.38, behind the S&P 500's +10.0%. Its worst day was Nov 17 (−15.3%), and its low came Feb 5 at $1.68.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.27 missed the $-0.05 estimate on $242,000.00 revenue (est. $10.8M).
−15.3%, the year's worst day · S&P 500 −0.9%
Story events cover the past 12 months · Times ET
NRX Pharmaceuticals closed at its lowest level of the year, 33.9% below where the year started.
−8.7% · S&P 500 −1.2%
EPS of $0.20 beat the $-0.08 estimate on $983,000.00 revenue (est. $7.0M).
+20.3% · S&P 500 −0.3%
In the Order, the President notes that, "It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and
+25.5% · S&P 500 −0.2%
EPS of $-0.04 beat the $-0.10 estimate on $1.1M revenue (est. $22.9M).
−5.0% · S&P 500 −0.1%
NRX Pharmaceuticals closed at its highest level of the year, 81.9% above where the year started.
+4.5% · S&P 500 +0.3%
No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufacturing and Controls, or other drug-related review matters.
+15.9% · S&P 500 +0.6%
EPS of $-0.44 missed the $-0.12 estimate on $1.1M revenue (est. $1.5M).
+4.9% · S&P 500 −0.5%
NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.
−14.7% · S&P 500 −1.8%
Where it ended: a close of $2.38 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.18, revenue est. $1.3M).
Nothing in the past 12 months.
All NRXP dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NRXP and SPY from Benzinga historical bars. Not investment advice.
